Maxim Group Reiterates Buy On Tekmira Pharma, $31 PT
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Tekmira Pharma (NASDAQ:TKMR) with a price target of $31.00.
Kolbert noted, “Tekmira announced the presentation of preclinical results characterizing TKM-HBV, a therapeutic agent targeting the human hepatitis B virus (HBV), at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society. Tekmira’s Chief Technical Officer, Dr. Ian MacLachlan, delivered a podium presentation entitled, “Update on the Preclinical Development of an LNP- Based HBV Therapeutic.” The conference took place in San Diego, California, from October 12 – 15, 2014. An extensive slide deck reviewed the scientific rationale, preclinical science, and goals of the therapy. Tekmira hopes to enter the clinic in 2015. It is moving the treatment paradigm from immune clearance to immune tolerance.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 1.8% and a 41.4% success rate. Kolbert has an 60.2% average return when recommending TKMR, and is ranked #1203 out of 3335 analysts.